← Back to all trials
Not Yet Recruiting
NCT07917039
A Phase Ⅱ Clinical Trial of SYH2072 Tablets in Participants With Primary Aldosteronism
Conditions: Primary Aldosteronism
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 60
Sponsor: InnovStone Therapeutics Limited
Location: Qilu Hospital of Shandong University Jinan Shandong
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to explore the efficacy and safety of SYH2072 tablets in Chinese participants with primary aldosteronism (PA) .
Eligibility Criteria
Inclusion Criteria:
1. Aged 18 years or older; male or female.
2. Documented diagnosis of primary aldosteronism (PA) before screening.
3. Receiving stable antihypertensive therapy.
4. Willing to discontinue mineralocorticoid receptor antagonists (MRA) or potassium-sparing diuretics.
5. Mean seated office systolic blood pressure (SBP) ≥140 mmHg and \
Source: ClinicalTrials.gov (NCT07917039). StuddyBuddy aggregates publicly available trial information.
